Acquired haemophilia A (AHA) is a rare bleeding disorder caused by the development of specific autoantibodies against naturally occurring factor VIII (FVIII). Although about half of cases are idiopathic, AHA may be associated with several non-neoplastic conditions, autoimmune disorders, as well as haematological malignancies, such as chronic lymphocytic leukaemia and lymphoma. The long-term suppression of inhibitors is one of the mainstays of the treatment of AHA. Apart from standard immunosuppressive treatments, rituximab has been proven to be effective in AHA.
The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A / D'Arena, G; Grandone, E; DI MINNO, Matteo; Musto, P; DI MINNO, Giovanni. - In: BLOOD TRANSFUSION. - ISSN 1723-2007. - (2016), pp. 255-261. [10.2450/2015.0090-15]